Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E127.20 EPS (ttm)1.09 Insider Own0.40% Shs Outstand75.54M Perf Week1.15%
Market Cap10.47B Forward P/E407.79 EPS next Y0.34 Insider Trans30.71% Shs Float61.32M Perf Month9.15%
Income86.90M PEG795.01 EPS next Q0.57 Inst Own76.40% Short Float8.56% Perf Quarter12.67%
Sales563.10M P/S18.60 EPS this Y-45.30% Inst Trans3.00% Short Ratio6.60 Perf Half Y61.50%
Book/sh9.57 P/B14.49 EPS next Y-59.76% ROA10.50% Target Price161.11 Perf Year11.19%
Cash/sh9.75 P/C14.22 EPS next 5Y0.16% ROE13.00% 52W Range82.51 - 154.89 Perf YTD31.07%
Dividend- P/FCF85.29 EPS past 5Y24.50% ROI10.70% 52W High-10.48% Beta0.74
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin94.60% 52W Low68.04% ATR4.67
Employees535 Current Ratio6.00 Sales Q/Q161.80% Oper. Margin45.30% RSI (14)62.29 Volatility2.81% 3.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.60% Profit Margin15.40% Rel Volume0.74 Prev Close140.29
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout0.00% Avg Volume796.00K Price138.65
Recom2.00 SMA202.75% SMA5012.07% SMA20023.34% Volume586,440 Change-1.17%
Oct-17-14Reiterated ROTH Capital Buy $185 → $188
Oct-14-14Reiterated ROTH Capital Buy $183 → $185
Aug-01-14Upgrade WallachBeth Hold → Buy
May-27-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
May-05-14Reiterated RBC Capital Mkts Outperform $150 → $110
Feb-21-14Reiterated Deutsche Bank Buy $170 → $180
Dec-18-13Initiated WallachBeth Hold $108
Sep-26-13Initiated Deutsche Bank Buy $170
Dec-12-12Reiterated Wedbush Outperform $93 → $110
Aug-24-12Initiated Stifel Nicolaus Hold
Aug-02-12Downgrade Needham Buy → Hold
May-17-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
May-17-12Reiterated Needham Buy $23 → $32
Feb-21-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
Dec-09-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
Dec-09-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
Dec-07-11Initiated Rodman & Renshaw Mkt Outperform $20
Nov-11-11Resumed Needham Buy $14
Jun-20-11Reiterated RBC Capital Mkts Outperform $10 → $15
Jun-07-10Reiterated Wedbush Outperform $8 → $16
Nov-14-14 01:04PM  PHARMACYCLICS INC Financials EDGAR Online Financials
Nov-12-14 04:07PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Nov-09-14 07:09PM  10-Q for Pharmacyclics, Inc. Company Spotlight
Nov-07-14 04:52PM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-06-14 09:29AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
09:09AM  IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting PR Newswire
08:30AM  Keith Lui Joins Versartis to Lead Global Marketing Efforts GlobeNewswire
Nov-05-14 11:00AM  Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca Zacks
Nov-04-14 04:30PM  Pharmacyclics tops Street 3Q forecasts AP
04:13PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:05PM  Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update PR Newswire
02:32PM  AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers PR Newswire
11:00AM  AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors PR Newswire
08:00AM  AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers PR Newswire
07:07AM  Q3 2014 Pharmacyclics Inc Earnings Release - After Market Close CCBN
Oct-22-14 01:40PM  Pharmacyclics Up on Label Expansion Efforts for Imbruvica Zacks
Oct-20-14 08:53AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:00AM  Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia PR Newswire
Oct-17-14 05:15PM  Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy Zacks
08:49AM  IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers PR Newswire
Oct-16-14 02:45PM  Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia PR Newswire
Oct-14-14 04:20PM  Bristol-Myers Collaborates for Opdivo-Imbruvica Combo Zacks
Oct-13-14 08:00AM  Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma Business Wire
Sep-30-14 04:15PM  PHARMACYCLICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Financial Stateme EDGAR Online
Sep-25-14 04:01PM  Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration PR Newswire
Sep-19-14 12:17PM  Gilead's Zydelig Approved In EU; Imbruvica In Wings at Investor's Business Daily
Sep-11-14 09:30AM  5 Stocks Breaking Out With Big Volume at TheStreet
Sep-08-14 01:02PM  Pharmacyclics Price Target Cut On Higher Spending at Investor's Business Daily
09:10AM  SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks at 24/7 Wall St.
Sep-03-14 06:11PM  Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership Zacks
01:20PM  Infinity Pharma Joins AbbVie On Blood Cancer Drug at Investor's Business Daily
Aug-29-14 04:15PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Aug-26-14 05:55PM  Celgene, Gilead Lead Big Biotech Stock Movers at Investor's Business Daily
Aug-20-14 07:13AM  Target Expected To Be Right On Target With Earnings Benzinga
Aug-18-14 04:05PM  Pharmacyclics Appoints Chief Commercial Officer PR Newswire
Aug-14-14 03:52PM  PHARMACYCLICS INC Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online
Aug-13-14 10:49AM  Pharmacyclics Has Edge Over Blood Cancer Competitors at TheStreet
Aug-08-14 08:01AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online
06:05AM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-04-14 06:02AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Aug-01-14 04:10PM  Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales Zacks
12:35PM  Pharmacyclics Q2 Earnings Get Mixed Reception at Investor's Business Daily
10:16AM  The Best Blood Cancer Drug Launch Ever? at Forbes
07:10AM  Pharmacyclics upgraded by WallachBeth Briefing.com
Jul-31-14 04:16PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:04PM  Pharmacyclics Reports Second Quarter 2014 Results PR Newswire
07:07AM  Q2 2014 Pharmacyclics Inc. Earnings Release - After Market Close CCBN
Jul-30-14 01:50PM  5 stocks to watch at MarketWatch
07:35AM  Pharmacyclics (PCYC) Jumps: Stock Rises 15% Zacks
Jul-28-14 07:00PM  Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 PR Newswire
05:00PM  Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Zacks
01:18PM  U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications PR Newswire
Jul-25-14 08:52AM  European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers PR Newswire
08:32AM  Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger at Motley Fool
Jul-24-14 07:38AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue? Zacks
Jul-23-14 06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool +7.57%
Jul-09-14 07:51PM  Is Pharmacyclics the Next Celgene? at Motley Fool
Jul-08-14 08:01AM  Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment at Seeking Alpha
06:00AM  3 Stocks Spiking on Unusual Volume at TheStreet
Jun-24-14 05:05PM  [video] Upside ahead for Vertex: Pro at CNBC
Jun-21-14 09:02AM  3 Stocks Crushed by the Market This Week at Motley Fool
Jun-19-14 05:39PM  Fire Up The Immuno-Oncology Powerhouses: John McCamant at Seeking Alpha
Jun-10-14 05:45PM  Pharmacyclics' Imbruvica Under FDA Priority Review Zacks
Jun-09-14 06:41PM  Pharmacyclics Investor's Business Daily
08:18AM  Pharmacyclics reports sNDA for Imbruvica accepted, priority review granted at theflyonthewall.com
08:00AM  Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted PR Newswire
Jun-06-14 01:03PM  PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
Jun-05-14 01:26PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
11:28AM  ASCO: Cancer Drug Showdown at Motley Fool
07:36AM  The Zacks Analyst Blog Highlights: Pharmacyclics, AbbVie, Gilead, Amgen and Celgene. Zacks
Jun-04-14 11:14AM  Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO Zacks
09:39AM  1 Biotech Steamrolling the Competition at Motley Fool
07:11AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Merck, Roche, Pharmacyclics and AbbVie Zacks
Jun-03-14 08:02AM  UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following Investor Event Benzinga
07:20AM  Gorman Rupp, American Vanguard, Pharmacyclics, GlaxoSmithKline and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day Zacks
Jun-02-14 01:26PM  IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study PR Newswire
01:25PM  Pharmacyclicss Imbruvica Continues to Set the Bar High for Cancer Drugs at Wall St. Cheat Sheet
12:20PM  Midday movers: Allergan, Valeant, US Steel & more at CNBC
11:10AM  Encouraging Data on Pharmacyclics/J&J Drug Zacks
10:42AM  US STOCKS-Wall St dips after manufacturing data, Google falls Reuters
09:44AM  Why these 3 biotech stocks are making big moves at CNBC
08:11AM  Why Clovis, Ariad, Pharmacyclics are on the move at CNBC
May-31-14 03:29PM  Pharmacyclics Leukemia Drug Beats Glaxos in Clinical Trial at Bloomberg
08:05AM  IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study PR Newswire
08:05AM  IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL PR Newswire
08:05AM  IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases PR Newswire
07:35AM  Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients at TheStreet
May-29-14 01:02PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
08:20AM  3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC) Benzinga
May-28-14 09:36AM  3 Stocks Crushed by the Market Last Week at Motley Fool
09:17AM  Doctors enthusiastic about Pharmacyclics Imbruvica, says JMP Securities at theflyonthewall.com
May-27-14 09:55AM  UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following IMS Launch Analysis Benzinga
09:01AM  Pharmacyclics downgraded to Sector Perform from Outperform at RBC Capital at theflyonthewall.com
09:01AM  Will This Downgrade Hurt Pharmacyclis (PCYC) Stock Today? at TheStreet
May-23-14 07:02PM  Why Pharmacyclics, Inc., Matador Resources Co, and Twitter Inc Are Today's 3 Worst Stocks at Motley Fool -7.35%
03:49PM  Mid-Afternoon Market Update: Nimble Storage Rallies As Pharmacyclics Shows Weakness Benzinga
01:40PM  Nasdaq stocks posting largest percentage decreases AP
01:16PM  Pharmacyclics down after announcing resignation of Paula Boultbee at theflyonthewall.com
10:16AM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
May-21-14 08:00AM  The Bull Thesis for Pharmacyclics Into ASCO '14 at TheStreet
Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghChief Financial OfficerNov 13Option Exercise61.601,00061,60039,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Option Exercise6.843,00020,5206,193Nov 17 04:30 PM
Soni Manmeet SinghChief Financial OfficerNov 13Sale141.441,000141,44238,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Sale141.303,000423,9023,193Nov 17 04:30 PM
Zanganeh MakyChief Operating OfficerNov 12Option Exercise7.195,93142,644216,243Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 12Sale137.965,931818,216210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Option Exercise32.381,50048,5701,705Nov 10 06:30 PM
Zanganeh MakyChief Operating OfficerNov 10Option Exercise2.3023,00052,900233,312Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 10Sale133.8323,0003,078,027210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Sale133.871,500200,805205Nov 10 06:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Option Exercise6.845,00034,2008,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerNov 07Option Exercise2.301,5513,567211,863Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 07Sale135.011,551209,401210,312Nov 12 06:07 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Sale134.505,000672,5003,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerSep 04Option Exercise2.305,00011,500215,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 04Sale122.005,000610,000210,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Option Exercise2.307,00016,100217,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Sale121.577,000850,980210,311Sep 04 05:54 PM
Love Richard BGeneral CounselAug 27Option Exercise32.381,50048,5701,704Aug 28 09:52 PM
Love Richard BGeneral CounselAug 27Sale124.001,500186,000204Aug 28 09:52 PM
Tan HeowChief Quality&Tech OperationsAug 21Option Exercise27.052,19659,4024,069Aug 22 02:45 PM
Tan HeowChief Quality&Tech OperationsAug 13Option Exercise27.0510,000270,50011,873Aug 13 05:27 PM
Tan HeowChief Quality&Tech OperationsAug 13Sale123.5810,0001,235,8081,873Aug 13 05:27 PM
McGreivy JesseChief Medical OfficerAug 07Option Exercise73.0934,0622,489,51534,062Aug 07 06:51 PM
McGreivy JesseChief Medical OfficerAug 07Sale120.9234,0624,118,6100Aug 07 06:51 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Option Exercise6.843,00020,5205,988Mar 07 06:06 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Option Exercise0.8615,00012,90053,004Mar 06 06:06 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Option Exercise25.946,253162,2037,992Mar 06 04:33 PM
McGreivy JesseChief Medical OfficerMar 05Option Exercise25.336,563166,2416,563Mar 06 04:35 PM
McGreivy JesseChief Medical OfficerMar 05Sale139.666,563916,5990Mar 06 04:35 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Sale140.756,253880,1151,739Mar 06 04:33 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Sale140.0015,0002,100,03338,004Mar 06 06:06 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Sale140.503,000421,5042,988Mar 07 06:06 PM
Chang Betty YVP, Research/BiologyMar 04Option Exercise10.2417,500179,23821,254Mar 05 08:15 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Option Exercise25.9413,747356,59715,486Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Option Exercise17.663,47261,3324,472Mar 06 02:46 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Sale137.0713,7471,884,3301,739Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Sale138.333,472480,2821,000Mar 06 02:46 PM
Chang Betty YVP, Research/BiologyMar 04Sale137.9717,5002,414,4843,754Mar 05 08:15 PM
van den Broek RichardDirectorFeb 27Sale144.9225,0003,622,99029,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 26Sale147.1325,6803,778,17054,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 25Sale147.7028,1554,158,49680,290Feb 28 05:26 PM
Hemmi GregoryVP Chemical OperationsDec 30Option Exercise0.7513,0009,75038,004Jan 02 01:15 PM
Tan HeowChief Quality&Tech OperationsDec 24Option Exercise27.051,50040,5751,669Dec 26 06:10 PM
Smith David DuaneDirectorDec 20Option Exercise1.921,0001,9203,000Dec 20 05:22 PM
Tan HeowChief Quality&Tech OperationsDec 19Option Exercise27.055,000135,2505,169Dec 20 02:44 PM
Tan HeowChief Quality&Tech OperationsDec 19Sale100.875,000504,352169Dec 20 02:44 PM
Hemmi GregoryVP Chemical OperationsDec 18Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 18Sale99.0410,000990,38025,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Sale102.0010,0001,020,00025,004Dec 18 07:30 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Option Exercise0.9122,83520,78034,332Dec 16 07:13 PM
Smith David DuaneDirectorDec 16Option Exercise1.926,50012,4808,500Dec 17 04:16 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Sale107.7222,8352,459,68111,497Dec 16 07:13 PM
Zanganeh MakyChief Operating OfficerDec 16Sale107.5520,0002,151,000210,107Dec 18 07:24 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Option Exercise0.9131,16528,36042,662Dec 16 07:13 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Sale107.8231,1653,360,11411,497Dec 16 07:13 PM